The collaboration is aimed at expanding patient access to therapies in chronic kidney disease, anaemia management and transplant care.

Emcure partners with Roche to enhance access to nephrology and transplant therapies for chronic kidney disease in India.

Rajji Mehdwan, Managing Director and CEO of Roche India & Neighbouring Markets, said that Emcure’s robust distribution network and clinical engagement will help ensure these medicines are accessible ...

Emcure Pharmaceuticals partners with Roche to distribute nephrology and transplant medicines in India, enhancing patient access to essential therapies.

For Roche's select brands in nephrology and transplant segment in India ...

Emcure Pharmaceuticals has signed an agreement with Roche to distribute select products from the nephrology and transplant medicine portfolio of the latter.

Emcure and Roche ink distribution pact strengthen nephrology and transplant care in India: Our Bureau, Bengaluru Monday, March 2, 2026, 17:10 Hrs [IST] Emcure Pharmaceuticals has ...

Emcure Pharmaceuticals has had its share of run-ins with the FDA in the past over the sterility of one of its Indian manufacturing plants. Now, it can notch one more black mark on its belt. The FDA ...

The new dosage variant is designed to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anaemia (IDA). DCGI-approved FCM is indicated for the ...

Emcure Pharmaceuticals and Schaeffler shares show strong bullish technical setups. Osho Krishan of Angel One recommend 'Buy' with defined stop losses and target prices.

Emcure Pharmaceuticals IPO subscription status: The initial public offering of Emcure Pharmaceuticals Ltd kickstarts for subscriptions today (Wednesday, July 3 ...

Emcure Pharmaceuticals IPO subscription status was 4.98 times, on the second day, as per BSE data.(https://www.emcure.com/) Emcure Pharmaceuticals IPO subscription ...